ACADIA Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-07-16
- Employees
- 598
- Market Cap
- $2.6B
- Website
- http://www.acadia.com
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 454
- Registration Number
- NCT04531982
- Locations
- 🇦🇷
623-Clinica Privada de Salud Mental Santa Teresa de Avila, La Plata, Argentina
🇧🇬586-Medical Center Mentalcare OOD, Plovdiv, Bulgaria
🇨🇿583-Narodni ustav dusevniho zdravi, Klecany, Czechia
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04292223
- Locations
- 🇺🇸
Global Health Research Center, Inc., Miami Lakes, Florida, United States
🇺🇸Parkinson's Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, United States
🇺🇸The Orthopedic Foundation, New Albany, Ohio, United States
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT04279314
- Locations
- 🇺🇸
Emory Genetics Clinical Trial Center, Atlanta, Georgia, United States
🇺🇸Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States
🇺🇸Kennedy Krieger Institute - Clinical Trials Unit, Baltimore, Maryland, United States
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT04181723
- Locations
- 🇺🇸
Kennedy Krieger Institute - Clinical Trials Unit, Baltimore, Maryland, United States
🇺🇸Rush University Children's Hospital, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital Harvard Medical School, Boston, Massachusetts, United States
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04164758
- Locations
- 🇺🇸
Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
🇺🇸Tucson Neuroscience Research, Tucson, Arizona, United States
🇺🇸Galiz Research, Hialeah, Florida, United States
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT04000009
- Locations
- 🇸🇰
Centrum Zdravia R.B.K., s.r.o., Svidnik, Slovakia
🇸🇰Liptovska nemocnice s poliklinikou MUDr. Ivana Stodolu, Psychiatricke oddelenie, Liptovsky Mikulas, Slovakia
🇸🇰EPAMED s r.o., Kosice, Slovakia
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT03968159
- Locations
- 🇺🇸
IPC Research, Waukesha, Wisconsin, United States
🇺🇸Collective Medical Research, LLC, Prairie Village, Kansas, United States
🇺🇸Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 595
- Registration Number
- NCT03623321
- Locations
- 🇨🇿
A-shine s.r.o./ Lekarna Centrum, Plzen, Czechia
🇷🇺Regional Specialized Psychiatric Hospital #2, Tonnel'nyy, Kochubeev District, Russian Federation
🇷🇺Federal Siberian Sci Clinical Center of Med and Bio, Krasnoyarsk, Russian Federation
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 784
- Registration Number
- NCT03575052
- Locations
- 🇵🇱
RCMed Oddzial Sochaczew, ul. _eromskiego 41A, Sochaczew, Poland
🇺🇸Boston Center Memory, Newton, Massachusetts, United States
🇺🇸Reliable Clinical Research, LLC, Hialeah, Florida, United States
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03482882
- Locations
- 🇺🇸
Associated Neurologists, P.C., Danbury, Connecticut, United States
🇺🇸ATP Clinical Research, Inc., Costa Mesa, California, United States
🇺🇸CNS Network, Torrance, California, United States